BAY-1816032 NEW
| Price | $32 | $77 | $128 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-30 |
Product Details
| Product Name: BAY-1816032 | CAS No.: 1891087-61-8 |
| Purity: 99.32% | Supply Ability: 10g |
| Release date: 2025/07/30 |
Product Introduction
Bioactivity
| Name | BAY-1816032 |
| Description | BAY-1816032 is a benzimidazole budding inhibition relieved homolog protein 1 kinase (BUB1) inhibitor with IC50 of 0.7 nM and is orally active and abolishes nocodazole-induced Thr-120 phosphorylation of histone H2A, a major BUB1 target protein, in HeLa cells with IC50 of 29 nM. |
| In vitro | METHODS: BAY-1816032 (0, 1.5625, 3.125, 6.25, 12.5, 25, 50 μM, 48 hours) treated ATC cells (TPC-1, 8505C), and CCK-8 assay was used to study cell viability. RESULTS BAY-1816032 treatment resulted in a decrease in ATC cell viability, with IC50 values ??of 4.230 μM in TPC-1 cells and 6.216 μM in 8505C cells. [2] METHODS: Colony formation assay, cell cycle, invasion, migration and wound healing assay were performed after ATC cells were treated with BAY-1816032 (0, 2.5, 5 μM). RESULTS BAY-1816032 can significantly reduce colony formation ability; BAY-1816032 can cause cell cycle arrest similar to siRNA; BAY-1816032 treatment can significantly hinder the invasion and migration of ATC cells in a dose-dependent manner. [2] |
| In vivo | METHODS: BAY-1816032 (100 mg/kg, oral, 24 days) was used to treat 8505C xenograft model mice to evaluate the anti-ATC activity and safety of BAY-1816032 in mice. RESULTS There was no significant difference in the body weight of each group of mice; the tumor weight of mice treated with BAY-1816032 was significantly reduced. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 0.1 mg/mL (insoluble) DMSO : 15 mg/mL (28.06 mM), Sonication and heating are recommended. |
| Keywords | Inhibitor | inhibit | BUB1 kinase | BUB1 | BAY-1816032 | BAY1816032 | BAY 1816032 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $40.00/1KG |
VIP4Y
|
ZhenYiBio Technology Inc
|
2022-01-14 | |
| $0.00/25kg |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-15 | |
| $32.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY